Last reviewed · How we verify
Mycophenolate to sirolimus switch
Mycophenolate to sirolimus switch is a Immunosuppressant combination therapy Small molecule drug developed by London Health Sciences Centre. It is currently FDA-approved for Organ transplant recipients (kidney, heart, liver) requiring immunosuppressive therapy optimization. Also known as: rapamune, rapamycin, mycophenolic mofetil, mycophenolic acid.
A therapeutic strategy that replaces mycophenolate mofetil with sirolimus to reduce immunosuppressive burden while maintaining graft protection in transplant recipients.
A therapeutic strategy that switches patients from mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibitor) to sirolimus (an mTOR inhibitor) to optimize immunosuppression in transplant recipients. Used for Organ transplant rejection prevention (switch strategy in transplant recipients).
At a glance
| Generic name | Mycophenolate to sirolimus switch |
|---|---|
| Also known as | rapamune, rapamycin, mycophenolic mofetil, mycophenolic acid, cellcept |
| Sponsor | London Health Sciences Centre |
| Drug class | Immunosuppressant combination therapy |
| Target | mTOR (sirolimus component); IMPDH (mycophenolate component being replaced) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
This represents a clinical protocol switch from mycophenolate (an inosine monophosphate dehydrogenase inhibitor that suppresses T and B cell proliferation) to sirolimus (an mTOR inhibitor with anti-proliferative and immunomodulatory effects). The switch aims to optimize long-term immunosuppressive therapy by leveraging sirolimus's distinct mechanism and potentially improved safety profile in certain transplant populations.
Approved indications
- Organ transplant recipients (kidney, heart, liver) requiring immunosuppressive therapy optimization
Common side effects
- Hyperlipidemia
- Thrombocytopenia
- Delayed wound healing
- Mouth ulcers
- Pneumonitis
Key clinical trials
- Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
- EVEROLD LONG TERM FOLLOW-UP
- Treg Modulation With CD28 and IL-6 Receptor Antagonists (PHASE1, PHASE2)
- Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response (PHASE4)
- Randomized Conversion of Calcineurin-Inhibitors in Renal Allograft Recipients (PHASE4)
- Mycophenolate Mofetil and Rapamycin as Secondary Intervention vs. Continuation of Calcineurin Inhibitors in Patients at Risk for Chronic Renal Allograft Failure (PHASE4)
- Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV) (PHASE4)
- mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mycophenolate to sirolimus switch CI brief — competitive landscape report
- Mycophenolate to sirolimus switch updates RSS · CI watch RSS
- London Health Sciences Centre portfolio CI
Frequently asked questions about Mycophenolate to sirolimus switch
What is Mycophenolate to sirolimus switch?
How does Mycophenolate to sirolimus switch work?
What is Mycophenolate to sirolimus switch used for?
Who makes Mycophenolate to sirolimus switch?
Is Mycophenolate to sirolimus switch also known as anything else?
What drug class is Mycophenolate to sirolimus switch in?
What development phase is Mycophenolate to sirolimus switch in?
What are the side effects of Mycophenolate to sirolimus switch?
What does Mycophenolate to sirolimus switch target?
Related
- Drug class: All Immunosuppressant combination therapy drugs
- Target: All drugs targeting mTOR (sirolimus component); IMPDH (mycophenolate component being replaced)
- Manufacturer: London Health Sciences Centre — full pipeline
- Therapeutic area: All drugs in Immunology / Transplantation
- Indication: Drugs for Organ transplant recipients (kidney, heart, liver) requiring immunosuppressive therapy optimization
- Also known as: rapamune, rapamycin, mycophenolic mofetil, mycophenolic acid, cellcept
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing